Chemistry:Aminopeptidase A inhibitor
From HandWiki
Aminopeptidase A inhibitors are a class of antihypertensive drugs that work by inhibiting the conversion of angiotensin II to angiotensin III by the aminopeptidase A enzyme. The first medication in this class is firibastat.[1][2][3] It is hypothesized that the drugs may be more effective in overweight people and those of African descent.[4]
References
- ↑ Blazek, Olivia; Bakris, George L (13 February 2023). "Novel Therapies on the Horizon of Hypertension Management". American Journal of Hypertension 36 (2): 73–81. doi:10.1093/ajh/hpac111. https://academic.oup.com/ajh/article-abstract/36/2/73/6749842.
- ↑ Ojha, Utkarsh; Ruddaraju, Sanjay; Sabapathy, Navukkarasu; Ravindran, Varun; Worapongsatitaya, Pitchaya; Haq, Jeesanul; Mohammed, Raihan; Patel, Vinod (2022). "Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension". American Journal of Cardiovascular Drugs 22 (3): 271–285. doi:10.1007/s40256-021-00510-9. ISSN 1175-3277. PMC 8651502. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651502/.
- ↑ Khosla, Jagjit; Aronow, Wilbert S.; Frishman, William H. (January 2022). "Firibastat: An Oral First-in-Class Brain Aminopeptidase A Inhibitor for Systemic Hypertension". Cardiology in Review 30 (1): 50–55. doi:10.1097/CRD.0000000000000360.
- ↑ Lazartigues, Eric; Llorens-Cortes, Catherine; Danser, A. H. Jan (2023). "New Approaches Targeting the Renin-Angiotensin System: Inhibition of Brain Aminopeptidase A, ACE2 Ubiquitination, and Angiotensinogen" (in English). Canadian Journal of Cardiology 0 (0). doi:10.1016/j.cjca.2023.06.013. ISSN 0828-282X. https://onlinecjc.ca/article/S0828-282X(23)00522-6/fulltext#secsectitle0025.
 |  |
